Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that numerous presentations and educational activities related to the investigation of several of the Company’s products or relevant disease states are scheduled to take place during Digestive Disease Week DDW ® 2012. DDW 2012 is being held in San Diego, CA, Saturday, May 19 – Tuesday, May, 22. Rifaximin-Related PresentationsPoster of Distinction #Mo1116: Pardi et al. “The Efficacy and Safety of Rifaximin vs. Vancomycin in the Treatment of Mild to Moderate C. difficile Infection: A Randomized Double-Blind Active Comparator Trial” Lecture Presentation #168, Saturday 2:30 p.m.: Mullen et al. “The Long Term Efficacy and Safety of Rifaximin in the Maintenance of Remission from Overt Hepatic Encephalopathy in Cirrhotic Patients” Poster #Tu1390: Lembo et al. “Improvement in Quality of Life of Patients with Irritable Bowel Syndrome with Diarrhea is Sustained for 10 Weeks Following a 2-Week Course of Rifaximin” Poster #Tu1403: Chang et al. “Safety and Tolerability Profile of Rifaximin for Treatment of IBS without Constipation: Results of a Pooled Analysis of Double-Blind, Placebo-Controlled Randomized Controlled Trials” Lecture Presentation #1041, Tuesday 11:30 a.m.: Pimentel et al. “Efficacy of Rifaximin for IBS without Constipation in Men and Women” Poster #Tu1406: Lembo et al. “Impact of Concurrent Use of PPIs or Antidepressants on Efficacy of Rifaximin for IBS without Constipation” Poster #Tu1076: Schoenfeld et al. “Predictive Value of Adequate Relief of Global IBS Symptoms During First Two Weeks of Rifaximin Use on Subsequent Relief of Daily IBS Symptoms and Daily Bloating Symptoms” Methylnaltrexone Bromide – Related PresentationsLecture Presentation #943a, Tuesday 8:30 a.m.: Rauck et al. “Oral Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Noncancer Pain” Lecture Presentation #420: Scarpellini et al. “Effect of Methylnaltrexone on Esophageal Function in Man” Poster # Mo1663: Anselmi et al. “Effects of Methylnaltrexone on Guinea Pig Gastrointestinal Motility” Poster # Tu1365: Magge et al. “The Efficacy of Peripherally Acting Opioid Antagonists in Opioid-Induced Constipation: Meta-Analysis of Controlled Clinical Trials” MoviPrep-Related PresentationsPoster #Sa1113: Shaheen et al. “Adjunctive Neostigmine/Glycopyrrolate Improves Colonoscopic Bowel Preparation and Efficacy in Subjects with Spinal Cord Injury” Poster #Su1273: Kump et al. “Efficacy and Tolerability of a New Reduced Volume Bowel Preparation Before Colonoscopy” Poster #Tu1372: Garsed et al. “Mode of Action of a Macrogol Formulation on Distribution of Intestinal Fluid: a MRI Study” Fecal Incontinence - Related PresentationCombined Clinical Symposium #L4460, Sunday 2:15 p.m.: “Management of Fecal Incontinence” About XIFAXAN® (rifaximin) 550 mg tabletsImportant Safety InformationXIFAXAN 550 mg is indicated for reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18 years of age. In the trials of XIFAXAN for HE, 91 percent of the patients were using lactulose concomitantly. XIFAXAN has not been studied in patients with MELD scores greater than 25, and only 8.6 percent of patients in the controlled trial had MELD scores over 19. There is increased systemic exposure in patients with more severe hepatic dysfunction. Therefore, caution should be exercised when administering XIFAXAN to patients with severe hepatic impairment (Child-Pugh C). XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, any of the rifamycin antimicrobial agents, or any of the components in XIFAXAN. Hypersensitivity reactions have included exfoliative dermatitis, angioneurotic edema and anaphylaxis.